272 related articles for article (PubMed ID: 18838678)
1. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase.
Zhang Z; Zhang Y; Ning G; Deb DK; Kong J; Li YC
Proc Natl Acad Sci U S A; 2008 Oct; 105(41):15896-901. PubMed ID: 18838678
[TBL] [Abstract][Full Text] [Related]
2. Losartan chemistry and its effects via AT1 mechanisms in the kidney.
Xu F; Mao C; Liu Y; Wu L; Xu Z; Zhang L
Curr Med Chem; 2009; 16(28):3701-15. PubMed ID: 19747145
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II type 1 receptor-associated protein deletion combined with angiotensin II stimulation accelerates the development of diabetic kidney disease in mice on a C57BL/6 strain.
Taguchi S; Azushima K; Yamaji T; Suzuki T; Abe E; Tanaka S; Hirota K; Tsukamoto S; Morita R; Kobayashi R; Kinguchi S; Yamashita A; Wakui H; Tamura K
Hypertens Res; 2024 Jan; 47(1):55-66. PubMed ID: 37957242
[TBL] [Abstract][Full Text] [Related]
4. Combining renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibition in experimental diabetes results in synergistic beneficial effects.
Cruz-López EO; Ye D; Stolk DG; Clahsen-van Groningen MC; van Veghel R; Garrelds IM; Poglitsch M; Domenig O; Alipour Symakani RS; Merkus D; Verdonk K; Jan Danser AH
J Hypertens; 2024 May; 42(5):883-892. PubMed ID: 38088400
[TBL] [Abstract][Full Text] [Related]
5. Brain Renin-Angiotensin System Blockade Attenuates Methamphetamine-Induced Hyperlocomotion and Neurotoxicity.
Jiang L; Zhu R; Bu Q; Li Y; Shao X; Gu H; Kong J; Luo L; Long H; Guo W; Tian J; Zhao Y; Cen X
Neurotherapeutics; 2018 Apr; 15(2):500-510. PubMed ID: 29464572
[TBL] [Abstract][Full Text] [Related]
6. Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats.
Zhong Y; Zhang X; Cai X; Wang K; Chen Y; Deng Y
PLoS One; 2014; 9(1):e85690. PubMed ID: 24454919
[TBL] [Abstract][Full Text] [Related]
7. Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
Kröpelin TF; de Zeeuw D; Andress DL; Bijlsma MJ; Persson F; Parving HH; Heerspink HJ
Clin J Am Soc Nephrol; 2015 Mar; 10(3):410-6. PubMed ID: 25568217
[TBL] [Abstract][Full Text] [Related]
8. A novel interaction between soluble epoxide hydrolase and the AT1 receptor in retinal microvascular damage.
Wang MH; Ibrahim AS; Hsiao G; Tawfik A; Al-Shabrawey M
Prostaglandins Other Lipid Mediat; 2020 Jun; 148():106449. PubMed ID: 32360774
[TBL] [Abstract][Full Text] [Related]
9. New clinical trials with vitamin D and analogs in renal disease.
Kumar R
Kidney Int; 2011 Oct; 80(8):793-6. PubMed ID: 21832981
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of RAS in diabetic nephropathy.
Yacoub R; Campbell KN
Int J Nephrol Renovasc Dis; 2015; 8():29-40. PubMed ID: 25926752
[TBL] [Abstract][Full Text] [Related]
11. Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice.
Alawi LF; Emberesh SE; Owuor BA; Chodavarapu H; Fadnavis R; El-Amouri SS; Elased KM
Physiol Rep; 2020 Feb; 8(3):e14364. PubMed ID: 32026607
[TBL] [Abstract][Full Text] [Related]
12. Renin-Angiotensin System Antagonism Protects the Diabetic Heart from Ischemia/Reperfusion Injury in Variable Hyperglycemia Duration Settings by a Glucose Transporter Type 4-Mediated Pathway.
Al-Kouh A; Babiker F; Al-Bader M
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259385
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies for diabetic nephropathy patients: beyond blockade of the Renin-Angiotensin system.
Tanios BY; Ziyadeh FN
Nephron Extra; 2012 Jan; 2(1):278-82. PubMed ID: 23599705
[TBL] [Abstract][Full Text] [Related]
14. Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system.
Santoro D; Caccamo D; Lucisano S; Buemi M; Sebekova K; Teta D; De Nicola L
Biomed Res Int; 2015; 2015():145828. PubMed ID: 26000281
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of
Fang H; Lin D; Li X; Wang L; Yang T
Front Pharmacol; 2023; 14():1287908. PubMed ID: 37841924
[No Abstract] [Full Text] [Related]
16. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.
Zhang Y; Deb DK; Kong J; Ning G; Wang Y; Li G; Chen Y; Zhang Z; Strugnell S; Sabbagh Y; Arbeeny C; Li YC
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F791-801. PubMed ID: 19535571
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy.
Wang Y; Deb DK; Zhang Z; Sun T; Liu W; Yoon D; Kong J; Chen Y; Chang A; Li YC
J Am Soc Nephrol; 2012 Dec; 23(12):1977-86. PubMed ID: 23123403
[TBL] [Abstract][Full Text] [Related]
18. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
[TBL] [Abstract][Full Text] [Related]
19. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice.
Reddy MA; Sumanth P; Lanting L; Yuan H; Wang M; Mar D; Alpers CE; Bomsztyk K; Natarajan R
Kidney Int; 2014 Feb; 85(2):362-73. PubMed ID: 24088954
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
